Efficacy and Safety of Inosine Pranobex in COVID‐19 Patients: A Multicenter Phase 3 Randomized Double‐Blind, Placebo‐Controlled Trial

MLA

Jayanthi C R, et al. “Efficacy and Safety of Inosine Pranobex in COVID‐19 Patients: A Multicenter Phase 3 Randomized Double‐Blind, Placebo‐Controlled Trial.” Advanced Therapeutics, vol. 5, Sept. 2022, p. 2200159. EBSCOhost, https://doi.org/10.1002/adtp.202200159.

APA

Jayanthi C R, Ashok K Swain, Ranganath T Ganga, Dnyaneshwar Halnor, Ajit Avhad, Mohd. Saif Khan, Ayan Ghosh, Sumer Sanjiv Choudhary, Anand Namdevrao Yannawar, Shubhangi Despande, Manish Patel, Krishna Prasad Anne, & Yogesh Bangar. (2022). Efficacy and Safety of Inosine Pranobex in COVID‐19 Patients: A Multicenter Phase 3 Randomized Double‐Blind, Placebo‐Controlled Trial. Advanced Therapeutics, 5, 2200159. https://doi.org/10.1002/adtp.202200159

Chicago

Jayanthi C R, Ashok K Swain, Ranganath T Ganga, Dnyaneshwar Halnor, Ajit Avhad, Mohd. Saif Khan, Ayan Ghosh, et al. 2022. “Efficacy and Safety of Inosine Pranobex in COVID‐19 Patients: A Multicenter Phase 3 Randomized Double‐Blind, Placebo‐Controlled Trial.” Advanced Therapeutics 5 (September): 2200159. doi:10.1002/adtp.202200159.